Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 10/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189294 | 0.90 | PTGES (0.37) | MAPTBACE1BACE2RAB9ASMN1; SMN2 | |
| SCHEMBL21189187 | 0.90 | RAB9A (0.37) | MEN1GAAMAPTKMT2ARAB9A | |
| SCHEMBL21189264 | 0.87 | NPC1 (0.44) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL19973466 | 0.87 | NPC1 (0.44) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21189330 | 0.87 | NPC1 (0.44) | MAPTRAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL21189253 | 0.87 | PTGES (0.37) | KMT2AALDH1A1AKR1C3 | |
| SCHEMBL21189250 | 0.86 | GRM4 (0.36) | MAPTRAB9ANPC1 | |
| SCHEMBL21189272 | 0.86 | GRM4 (0.36) | MEN1MAPTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL21189353 | 0.85 | PTGES (0.36) | MAPTRAB9ASMN1; SMN2NPC1AKR1C3 | |
| SCHEMBL21189337 | 0.84 | P2RX7 (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | MEN1 1933/4885GAA 1661/4885MAPT 3165/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | MEN1 1933/4885GAA 1661/4885MAPT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.